Skip to main content
Erschienen in: Strahlentherapie und Onkologie 2/2014

01.02.2014 | Original article

Salvage prostate HDR brachytherapy combined with interstitial hyperthermia for local recurrence after radiation therapy failure

verfasst von: A.M. Kukiełka, M. Hetnał, T. Dąbrowski, T. Walasek, P. Brandys, D. Nahajowski , R. Kudzia, D. Dybek, M. Reinfuss

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of the present retrospective study is to evaluate toxicity and early clinical outcomes of interstitial hyperthermia (IHT) combined with high-dose rate (HDR) brachytherapy as a salvage treatment in patients with biopsy-confirmed local recurrence of prostate cancer after previous external beam radiotherapy.

Patients and methods

Between September 2008 and March 2013, 25 patients with local recurrence of previously irradiated prostate cancer were treated. The main eligibility criteria for salvage prostate HDR brachytherapy combined with interstitial hyperthermia were biopsy confirmed local recurrence and absence of nodal and distant metastases. All patients were treated with a dose of 30 Gy in 3 fractions at 21-day intervals. We performed 62 hyperthermia procedures out of 75 planned (83 %). The aim of the hyperthermia treatment was to heat the prostate to 41–43 °C for 60 min. Toxicity for the organs of the genitourinary system and rectum was assessed according to the Common Terminology Criteria for Adverse Events (CTCAE, v. 4.03). Determination of subsequent biochemical failure was based on the Phoenix definition (nadir + 2 ng/ml).

Results

The median age was 71 years (range 62–83 years), the median initial PSA level was 16.3 ng/ml (range 6.37–64 ng/ml), and the median salvage PSA level was 2.8 ng/ml (1.044–25.346 ng/ml). The median follow-up was 13 months (range 4–48 months). The combination of HDR brachytherapy and IHT was well tolerated. The most frequent complications were nocturia, weak urine stream, urinary frequency, hematuria, and urgency. Grade 2 rectal hemorrhage was observed in 1 patient. No grade 3 or higher complications were observed. The 2-year Kaplan–Meier estimate of biochemical control after salvage treatment was 74 %. The PSA in 20 patients decreased below the presalvage level, while 11 patients achieved a PSA nadir < 0.5 ng/ml. All patients are still alive. Of the 7 patients who experienced biochemical failure, bone metastases were found in 2 patients.

Conclusion

IHT in combination with salvage HDR brachytherapy is a well tolerated and effective treatment.
Literatur
1.
Zurück zum Zitat Kuban DA, el-Mahdi AM, Schellhammer PF (1989) Prognosis in patients with local recurrence after definitive irradiation for prostatic carcinoma. Cancer 63:2421–2425PubMedCrossRef Kuban DA, el-Mahdi AM, Schellhammer PF (1989) Prognosis in patients with local recurrence after definitive irradiation for prostatic carcinoma. Cancer 63:2421–2425PubMedCrossRef
2.
Zurück zum Zitat D’Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974CrossRef D’Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974CrossRef
3.
Zurück zum Zitat Lee WR, Hanks GE, Hanlon A (1997) Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol 15:230–238PubMed Lee WR, Hanks GE, Hanlon A (1997) Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol 15:230–238PubMed
4.
Zurück zum Zitat Roach M, Hanks G, Thames H et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65(4):965–974PubMedCrossRef Roach M, Hanks G, Thames H et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65(4):965–974PubMedCrossRef
5.
Zurück zum Zitat Arrayeh E, Westphalen AC, Kurhanewicz J et al (2012) Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys 82(5):e787–e793PubMedCentralPubMedCrossRef Arrayeh E, Westphalen AC, Kurhanewicz J et al (2012) Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys 82(5):e787–e793PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer, version 2.2013. NCCN; 2013. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed 26 November 2013 NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer, version 2.2013. NCCN; 2013. http://​www.​nccn.​org/​professionals/​physician_​gls/​pdf/​prostate.​pdf.​ Accessed 26 November 2013
7.
Zurück zum Zitat Agarwal PK, Sadetsky N, Konety BR et al (2008) Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 112(2):307–314PubMedCrossRef Agarwal PK, Sadetsky N, Konety BR et al (2008) Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 112(2):307–314PubMedCrossRef
8.
Zurück zum Zitat Nguyen PL, D’Amico AV, Lee AK et al (2007) Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 110(7):1417–1427PubMedCrossRef Nguyen PL, D’Amico AV, Lee AK et al (2007) Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 110(7):1417–1427PubMedCrossRef
9.
Zurück zum Zitat Ryu S, Brown SL, Kim SH et al (1996) Preferential radiosensitization of human prostatic carcinoma cells by mild hyperthermia. Int J Radiat Oncol Biol Phys 34(1):133–138PubMedCrossRef Ryu S, Brown SL, Kim SH et al (1996) Preferential radiosensitization of human prostatic carcinoma cells by mild hyperthermia. Int J Radiat Oncol Biol Phys 34(1):133–138PubMedCrossRef
10.
Zurück zum Zitat Peschke P, Hahn EW, Wolber G et al (1996) Interstitial radiation and hyperthermia in the Dunning R3327 prostate tumour model: therapeutic efficacy depends on radiation dose-rate, sequence and frequency of heating. Int J Radiat Biol 70(5):609–616PubMedCrossRef Peschke P, Hahn EW, Wolber G et al (1996) Interstitial radiation and hyperthermia in the Dunning R3327 prostate tumour model: therapeutic efficacy depends on radiation dose-rate, sequence and frequency of heating. Int J Radiat Biol 70(5):609–616PubMedCrossRef
11.
Zurück zum Zitat Van Vulpen M, De Leeuw AA, Raaymakers BW et al (2004) Radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate cancer: preliminary results. BJU Int 93(1):36–41CrossRef Van Vulpen M, De Leeuw AA, Raaymakers BW et al (2004) Radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate cancer: preliminary results. BJU Int 93(1):36–41CrossRef
12.
Zurück zum Zitat Maluta S, Dall’Oglio S, Romano M et al (2007) Conformal radiotherapy plus local hyperthermia in patients affected by locally advanced high risk prostate cancer: preliminary results of a prospective phase II study. Int J Hyperthermia 23(5):451–456PubMedCrossRef Maluta S, Dall’Oglio S, Romano M et al (2007) Conformal radiotherapy plus local hyperthermia in patients affected by locally advanced high risk prostate cancer: preliminary results of a prospective phase II study. Int J Hyperthermia 23(5):451–456PubMedCrossRef
13.
Zurück zum Zitat Tilly W, Gellermann J, Graf R, Hildebrandt B et al (2005) Regional hyperthermia in conjunction with definitive radiotherapy against recurrent or locally advanced prostate cancer T3 pN0 M0. Strahlenther Onkol 181(1):35–41PubMedCrossRef Tilly W, Gellermann J, Graf R, Hildebrandt B et al (2005) Regional hyperthermia in conjunction with definitive radiotherapy against recurrent or locally advanced prostate cancer T3 pN0 M0. Strahlenther Onkol 181(1):35–41PubMedCrossRef
14.
Zurück zum Zitat Kukiełka AM, Hetnał M, Brandys P et al (2013) Interstitial hyperthermia of the prostate in combination with brachytherapy: an evaluation of feasibility and early tolerance. Strahlenther Onkol 189(6):467–475PubMedCrossRef Kukiełka AM, Hetnał M, Brandys P et al (2013) Interstitial hyperthermia of the prostate in combination with brachytherapy: an evaluation of feasibility and early tolerance. Strahlenther Onkol 189(6):467–475PubMedCrossRef
15.
Zurück zum Zitat Emami B, Stauffer P, Dewhirst MW et al (1991) RTOG quality assurance guidelines for interstitial hyperthermia. Int J Radiat Oncol Biol Phys 20(5):1117–1124PubMedCrossRef Emami B, Stauffer P, Dewhirst MW et al (1991) RTOG quality assurance guidelines for interstitial hyperthermia. Int J Radiat Oncol Biol Phys 20(5):1117–1124PubMedCrossRef
16.
Zurück zum Zitat Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40. Accessed 26 November 2013 Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. http://​ctep.​cancer.​gov/​protocolDevelopm​ent/​electronic_​applications/​ctc.​htm#ctc_40. Accessed 26 November 2013
17.
Zurück zum Zitat Lee B, Shinohara K, Weinberg V et al (2007) High Dose Rate (HDR) brachytherapy salvage for local prostate recurrence after radiotherapy: the UCSF experience. Int J Rad Onc Biol Phys 67(4):1106–1112CrossRef Lee B, Shinohara K, Weinberg V et al (2007) High Dose Rate (HDR) brachytherapy salvage for local prostate recurrence after radiotherapy: the UCSF experience. Int J Rad Onc Biol Phys 67(4):1106–1112CrossRef
18.
Zurück zum Zitat Chen CP, Weinberg V, Shinohara K et al (2013) Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiotherapy: 5-year outcomes. Int J Radiat Oncol Biol Phys 86(2):324–329PubMedCrossRef Chen CP, Weinberg V, Shinohara K et al (2013) Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiotherapy: 5-year outcomes. Int J Radiat Oncol Biol Phys 86(2):324–329PubMedCrossRef
19.
Zurück zum Zitat Jo Y, Fujii T, Hara R et al (2011) Salvage high-dose-rate brachytherapy for local prostate cancer recurrence after radiotherapy—preliminary results. BJU Int 109:835–839PubMedCrossRef Jo Y, Fujii T, Hara R et al (2011) Salvage high-dose-rate brachytherapy for local prostate cancer recurrence after radiotherapy—preliminary results. BJU Int 109:835–839PubMedCrossRef
20.
Zurück zum Zitat Tharp M, Hardacre M, Bennett R et al (2008) Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer. Brachytherapy 7:231–236PubMedCrossRef Tharp M, Hardacre M, Bennett R et al (2008) Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer. Brachytherapy 7:231–236PubMedCrossRef
21.
Zurück zum Zitat Łyczek J, Kawczyńska MM, Garmol M et al (2009) HDR brachytherapy as a solution in recurrences of locally advanced prostate cancer. J Contemp Brachyther 1(2):105–108 Łyczek J, Kawczyńska MM, Garmol M et al (2009) HDR brachytherapy as a solution in recurrences of locally advanced prostate cancer. J Contemp Brachyther 1(2):105–108
22.
Zurück zum Zitat Gawkowska-Suwińska M, Fijałkowski M, Białas B et al (2009) Salvage brachytherapy for local recurrences of prostate treated previously with radiotherapy. J Contemp Brachyther 1(4):211–215 Gawkowska-Suwińska M, Fijałkowski M, Białas B et al (2009) Salvage brachytherapy for local recurrences of prostate treated previously with radiotherapy. J Contemp Brachyther 1(4):211–215
23.
Zurück zum Zitat Lahmer G, Lotter M, Kreppner S et al (2013) Protocol-based image-guided salvage brachytherapy: early results in patients with local failure of prostate cancer after radiation therapy. Strahlenther Onkol 189(8):668–674PubMedCrossRef Lahmer G, Lotter M, Kreppner S et al (2013) Protocol-based image-guided salvage brachytherapy: early results in patients with local failure of prostate cancer after radiation therapy. Strahlenther Onkol 189(8):668–674PubMedCrossRef
24.
Zurück zum Zitat Prionas SD, Kapp DS, Goffinet DR et al (1994) Thermometry of interstitial hyperthermia given as an adjuvant to brachytherapy for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 28(1):151–162PubMedCrossRef Prionas SD, Kapp DS, Goffinet DR et al (1994) Thermometry of interstitial hyperthermia given as an adjuvant to brachytherapy for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 28(1):151–162PubMedCrossRef
25.
Zurück zum Zitat Ramey SJ, Marshall DT (2013) Re-irradiation for salvage of prostate cancer failures after primary radiotherapy. World J Urol31:1339–1345 Ramey SJ, Marshall DT (2013) Re-irradiation for salvage of prostate cancer failures after primary radiotherapy. World J Urol31:1339–1345
26.
Zurück zum Zitat Beyer DC (2003) Brachytherapy for recurrent prostate cancer after radiation therapy. Semin Radiat Oncol 13:158–165PubMedCrossRef Beyer DC (2003) Brachytherapy for recurrent prostate cancer after radiation therapy. Semin Radiat Oncol 13:158–165PubMedCrossRef
Metadaten
Titel
Salvage prostate HDR brachytherapy combined with interstitial hyperthermia for local recurrence after radiation therapy failure
verfasst von
A.M. Kukiełka
M. Hetnał
T. Dąbrowski
T. Walasek
P. Brandys
D. Nahajowski
R. Kudzia
D. Dybek
M. Reinfuss
Publikationsdatum
01.02.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 2/2014
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-013-0486-z

Weitere Artikel der Ausgabe 2/2014

Strahlentherapie und Onkologie 2/2014 Zur Ausgabe

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.